U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07839793) titled 'A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients' on Sept. 18.
Brief Summary: Flexilev is a Parkinson's disease medicine made of small, dissolvable tablets containing low doses of levodopa and carbidopa, allowing doses to be adjusted in small, precise steps. OraFID is a new mechanical device that dispenses the exact number of tablets needed, with better than 99% accuracy, in amounts from 1 to 20 tablets. An optional companion app, Levilog, reminds patients when to take their dose and records how much medicine (tablets and milligrams) was taken.
This 12-week study will mainly assess how acceptable ...